Silymarin, a promising pharmacological agent for treatment of diseases

Iranian Journal of Basic Medical Sciences

Volumn 14, Issue 4, 2011, Pages 308-317

  Karimi, Gholamreza ^a   Vahabzadeh, Maryam ^b   Lari, Parisa ^b   Rashedinia, Marziyeh ^b   Moshiri, Mohammad ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antioxidant; Cancer; Liver; Medicinal plant; Silymarin

Indexed keywords

ALCOHOL; ALPHA AMANITIN; AMIODARONE; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CARBON TETRACHLORIDE; CASPASE 3; CELL NUCLEUS RECEPTOR; CISPLATIN; CYTOCHROME C; DAUNORUBICIN; DOXORUBICIN; ESTROGEN RECEPTOR; GALACTOSAMINE; GLYCOPROTEIN P; LIVERGOL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARACETAMOL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SILIBININ; SILIBININ PHOSPHATIDYLCHOLINE COMPLEX; SILIDIANIN; SILYBUM MARIANUM EXTRACT; SILYMARIN; SUPEROXIDE DISMUTASE; THALLIUM; THIOACETAMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINBLASTINE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTHRALGIA; ARTICLE; BLADDER CANCER; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER PREVENTION; CELL PROTECTION; CELL TRANSPORT; COLON CANCER; DEFECATION DISORDER; DEPRESSION; DIABETIC NEPHROPATHY; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DOSAGE FORM; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; ESTROGEN ACTIVITY; FERTILIZATION IN VITRO; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMOLYSIS; HUMAN; IMMUNOMODULATION; LIVER CARCINOMA; LIVER PROTECTION; LIVER TOXICITY; LUNG CANCER; LUNG DISEASE; MULTIDRUG RESISTANCE; MYOFIBROBLAST; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OVARY CANCER; OVARY FOLLICLE DEVELOPMENT; PERITONEAL DIALYSIS; PROSTATE CANCER; PROSTATE DISEASE; PROTEIN BINDING; PRURITUS; RENAL PROTECTION; SILYBUM MARIANUM; SKIN CANCER; SKIN MANIFESTATION; URTICARIA; UTERINE CERVIX CANCER; VIRUS HEPATITIS;

EID: 79960182676     PISSN: 20083866     EISSN: 20083874     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Kren V, Walterova D. Silybin and Silymarin - New effects and applications. Biomed Papers 2005; 149:29-41.
2. Dermarderosin A. The review of natural products. 1st ed. United States of America: Facts and Comparisions; 2001.
3. Mayer KE, Mayer RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepatitis 2005; 12:559-567.
4. Saller R, Melzer J, Reichling J, Brignoli R, Meier R. An updated systematic review of the pharmacology of silymarin. Forsch Komp Klas Nat 2007; 14:70-80.
5. Cesanow N, Fleminh H, Kelly GA. PDR for nonprescription drugs, dietary supplements,and herbs. 27th ed. Montvale: Thomson PDR; 2006.
6. Kaur M, Agarwal R. Silymarin and epithelial cancer chemoprevention: How close we are to bedside? Toxicol Appl Pharm 2007; 224:350-359.
7. Karimi G, Ramezani M, Tahoonian Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Complement Alternat Med 2005; 2:383-386.
8. Basiglio CL, Sanchez Pozzi EJ, Mottino AD, Roma MG. Differential effects of silymarin and its active component silybinin on plasma membrane stability and hepatocellular lysis. Chem Biol Interact 2009; 179:297-303.
9. Gazak R, Walterova D, Kren V. Silybin and silymarin - New and emerging applications in medicine. Curr Med Chem 2007; 14:315-338.
10. WenWu J, Lin L, Tsai T. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol 2009; 121:185-193.
11. Ramakrishnan G, Lo Muzio L, Elinos-Baez CM, Jagan S, Augustine TA, Kamaraj S, et al. Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells. Cell Prolif 2009; 42:229-40.
12. Toklu HZ, Tunali-Akbay T, Erkanli G, Yuksel M, Ercan F, Sener G. Silymarin, the antioxidant component of silybum marianum, protects against burn-induced oxidative skin injury. Burns 2007; 33:908-916.
13. Eminzade S, Uraz F, Izzettin FV. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals. Nutr Metab 2008; 5.
14. Katiyar SK, Roy AM, Baliga MS. Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation. Mol Cancer Ther 2005; 4:207-216.
15. Shaker E, Mahmoud H, Mnaa S. Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage. Food Chem Toxicol 2010; 48:803-6.
16. Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, et al. Silymarin inhibits in vitro tcell proliferation and cytokine production in hepatitis c virus infection. Gastroenterology 2010; 138:671-681.
17. Song Z, Song M, Lee DYW, Liu Y, Deaciuc IV, McClain CJ. Silymarin prevents palmitate-induced lipotoxicity in HepG2 cells: involvement of maintenance of Akt kinase activation. Basic Clin Pharmacol Toxicol 2007; 101:262-8.
18. Shaker E, Mahmoud H, Mnaa S. Silymarin, the antioxidant component and silybum marianum extracts prevent liver damage. Food Chem Toxicol 2010; 48:803-806.
19. Upadhyay G, Tiwari MN, Prakash O, Jyoti A, Shanker R, Singh MP. Involvement of multiple molecular events in pyrogallol-induced hepatotoxicity and silymarin-mediated protection: Evidence from gene expression profiles. Food Chem Toxicol 2010; 48:1660-1670.
20. Polyak SJ, Morishima C, Shuhart MC. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized silymarin. Gastroenterology 2007; 132:1925-1936.
21. Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, et al. Silybinin and related compounds are direct inhibitors of hepatitis c virus rna-dependent rna polymerase. Gastroenterology 2010; 138:1112-1122.
22. Miranda SR, Jin KL, Brouwer KLR, Wen Z, Smith PC, Hawke RL. Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: Role of multidrug resistance-associated protein 2 (Abcc2). Drug Metab Dispos 2008; 36:2219-2226.
23. Pradeep K, Mohan CVR, Gobianand K, Karthikeyan S. Silymarin: An effective hepatoprotective agent against diethylnitrosamine- induced hepatotoxicity in rats. Pharm Biol 2007; 45:707-714.
24. Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Digest Liver Dis 2007; 39:293-304.
25. Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DYW. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-B signaling, and HCV infection by standardized silymarin. Gastroenterol 2007; 132:1925-1936.
26. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001; 61:2035-2063.
27. Tyagi AK, Agarwal C, Chan DC, Agarwal R. Synergistic anti- cancer effects of silybinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinomaMCF-7 and MDAMB468 cells. Oncol Rep 2004a; 11:493-499.
28. Tyagi A, Agarwal C, Harrison G, Glode L M, Agarwal R. Silybinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis 2004b; 25:1711-1720.
29. Chu SC, Chiou HL, Chen PN, Yang SF, Hsieh YS. Silybinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinog 2004; 40:143-149.
30. Lahiri-Chatterjee M, Katiyar SK, Mohan RR, Agarwal R. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res 1999; 59:622-632.
31. Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R. Silymarin and silybinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silybinin with flavanolignan mixture silymarin. Oncogene 2006; 25:1053-1069.
32. Thelen P, Jarry H, Ringert RH, Wuttke W. Silybinin down-regulates prostate epithelium-derived Ets transcription factor in LNCaP prostate cancer cells. Planta Med 2004; 70:397-400.
33. Rana P, Agarwal S, Agarwal R. Prostate cancer chemoprevention by silybinin: bench to bedside. Mol Carcinog 2006; 45:436-442
34. Varghese L, Agarwal C, Tyagi A, Singh RP, Agarwal R. Silybinin efficacy against human hepatocellular. Carcinoma Clin Cancer Res 2005; 11:8441-8448.
35. Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, Tecklenburg M, Sclafani RA, et al. Silybinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 2003; 22: 8271-8282.
36. Li LH, Wu LJ, Jiang YY, Tashiro S, Onodera S, Uchiumi F, et al. Silymarin enhanced cytotoxic effect of anti-Fas agonistic antibody CH11 on A375-S2 cells. J Asian Nat Prod Res 2007; 9:593-602.
37. Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett 2008; 352-362
38. Ramakrishnan G, Augustine TA, Jagan S, Vinodhkumar R, Devaki T. Effect of silymarin on Nnitrosodiethylamine induced hepatocarcinogenesis in rats. Exp Oncol 2007; 29:39-44.
39. Szkudelski T. The mechanism of alloxan and streptozocin action in B cells of the rat pancreas. Physiol Res 2001; 50:536-546.
40. Sha S, Baliga R, Rajapurkar M, Fonseca V. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007; 18:16-28.
41. Soto C, Mena R, Luna J, Cerbón M, Larrieta E, Vital P, et al. Silymarin induces recovery of pancreatic function after alloxan damage in rats. Life Sci 2004; 75:2167-2180.
42. Soto C, Pérez J, García V, Uría E, Vadillo M, Raya L. Effect of silymarin on kidneys of rats suffering from alloxan-induced diabetes mellitus. Phytomedicine 2010; 17:1090-1094.
43. Varzi HN, Esmailzadeh S, Morovvati H, Avizeh R, Shahriari A, Givi ME.Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity in dogs. J Vet Pharmacol Ther 2007; 30:477-481.
44. Karimi G, Ramezani M, Tahoonian Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Complment Alternat 2005; 2:383-386.
45. Karimi G, Fallah Huseini H, Ramezani M, Tahoonian Z. Protective effect of silybum marianum (l.) gaertn. seeds extract and silymarin against cisplatin-induced acute nephrotoxicity in rats. J Med Plants 2005; 4:42-45.
46. Kaur G, Athar M, Alam MS. Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion response. Invest New Drugs 2010; 28:703-13.
47. Nazemian F, Karimi GH, Moatamedi M, Charkazi S, Shamsara J, Moohammadpour AH. Effect of Silymarin administration on TNF-α serum concentration in peritoneal dialysis patients. Phytother Res 2010; 24:1654-1657.
48. Galhardi F, Mesquita K, Monserrat JM, Barros DM. Effect of silymarin on biochemical parameters of oxidative stress in aged and young rat brain. Food Chem Toxicol 2009; 47:2655-60.
49. Nencini C, Giorgi G, Micheli L. Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine 2007; 14:129-135.
50. Davies K J. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. IUBMB Life 2000; 50:279-289.
51. Metodiewa D, Koska C. Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro)toxicity events and neurological disorders. Neurotox Res 2000; 1:197-233.
52. Baluchnejadmojarad T, Roghani M, Mafakheri M. Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: involvement of estrogen receptors and oxidative stress. Neurosci Lett 2010; 480:206-210.
53. Karimi G, Saradeghi Keisari M. Evaluation of antidepressant effect of ethanolic and aqueous extracts of Silybum marianum L. seed in mice. J Med Plants 2007; 6:38-43.
54. Gharagozloo M, Velardi E, Bruscoli S, Agostini M, Di Sante M, Donato V, et al. Silymarin suppress CD4+ T cell activation and proliferation: Effects on NFκ-B activity and IL-2 production. Pharmacol Res 2010; 61:405-409.
55. Soto PC, Sánchez RM, Uría CE, Favari PL. Silymarin effect in the pancreas of alloxan-induced diabetes mellitus in the rat. Rev Mex Cien Farm 2002; 33:5-10.
56. Soto C, Recoba R, Barrón H, Alvarez C, Favari L. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comp Biochem Physiol C Toxicol Pharmacol 2003; 136:205-12.
57. Karimi GH, Hassanzadeh M, Mehri S. Protective effects of Silymarin against free radical-induced erythrocyte lysis. J Alternat Complement Med 2006; 3.
58. Psotová J, Chlopčíková S, Miketová P, Hrbáč J, Šimánek V. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. part III. apigenin, baicalelin, kaempherol, luteolin and quercetin. Phytother Res 2004; 18:516-521.
59. El-Shitany NA, Hegazy S, El-desoky K. Evidences for antiosteoporotic and selective estrogen receptor modulator activity of silymarin compared with ethinylestradiol in ovariectomized rats. Phytomedicine 2010; 17:116-125.
60. Kiruthiga PV, Pandian SK, Devi KP. Silymarin protects PBMC against B(a)P induced toxicity by replenishing redox status and modulating glutathione metabolizing enzymes-an in vitro study. Toxicol Appl Pharmacol 2010; 247:116-128.